PT  - JOURNAL ARTICLE
AU  - Galli, Margherita
AU  - Zardini, Agnese
AU  - Gamshie, Worku Nigussa
AU  - Santini, Stefano
AU  - Tsegaye, Ademe
AU  - Trentini, Filippo
AU  - Marziano, Valentina
AU  - Guzzetta, Giorgio
AU  - Manica, Mattia
AU  - d’Andrea, Valeria
AU  - Putoto, Giovanni
AU  - Manenti, Fabio
AU  - Ajelli, Marco
AU  - Poletti, Piero
AU  - Merler, Stefano
TI  - Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply
AID  - 10.1101/2022.07.28.22278142
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.28.22278142
4099  - http://medrxiv.org/content/early/2022/07/31/2022.07.28.22278142.short
4100  - http://medrxiv.org/content/early/2022/07/31/2022.07.28.22278142.full
AB  - Background The worldwide inequitable access to vaccination claims for a re-assessment of policies that could minimize the COVID-19 burden in low-income countries. An illustrative example is what occurred in Ethiopia, where nine months after the launch of the national vaccination program in March 2021, only 3% of the population received two doses of COVID-19 vaccine. In the meantime, a new wave of cases caused by the emergence of Delta variant of SARS-CoV-2 was observed between July and November 2021.Methods We used a SARS-CoV-2 transmission model to estimate the level of immunity accrued before the launch of vaccination in the Southwest Shewa Zone (SWSZ) and to evaluate the impact of alternative age priority vaccination targets in a context of limited vaccine supply. The model was informed with available epidemiological evidence and detailed contact data collected across different socio-demographic settings.Results We found that, during the first year of the pandemic, 46.1-58.7% of SARS-CoV-2 infections and 24.9-48% of critical cases occurred in SWSZ were likely associated with infectors under 30 years of age. During the Delta wave, the contribution of this age group in causing critical cases was estimated to increase to 66.7-70.6%. However, our findings suggest that, when considering the vaccine product available at the time (ChAdOx1 nCoV-19; 65% efficacy against infection after 2 doses), prioritizing the elderly for vaccination remained the best strategy to minimize the disease burden caused by Delta, irrespectively to the number of available doses. Vaccination of all individuals aged 50□years or older would have averted 40 (95%CI: 18-60), 90 (95%CI: 61-111), and 62 (95%CI: 21-108) critical cases per 100,000 residents in urban, rural, and remote areas, respectively. Vaccination of all individuals aged 30□years or more would have averted an average of 86-152 critical cases per 100,000 individuals, depending on the setting considered.Conclusions Despite infections among children and young adults likely caused 70% of critical cases during the Delta wave in SWSZ, most vulnerable ages should remain a key priority target for vaccination against COVID-19.Competing Interest StatementM.A. has received research funding from Seqirus. The funding is not related to COVID-19. All other authors declare no competing interest.Funding StatementThis work was supported by the Italian Ministry of Foreign Affairs and International Cooperation within the project entitled Rafforzamento del sistema di sorveglianza e controllo delle malattie infettive in Etiopia (AID 011330). The funders had no role in the study design, data collection and analysis, interpretation, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript